ARTICLE | Company News
Eli Lilly, Yabao Pharmaceutical Group deal
October 26, 2015 7:00 AM UTC
The companies partnered to co-develop Lilly’s sodium-glucose cotransporter 1 (SGLT1) inhibitor to treat diabetes. Yabao received Chinese rights to develop and commercialize the compound, while Lilly ...